{"id":"NCT02256488","sponsor":"Novartis Vaccines","briefTitle":"Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects","officialTitle":"A Phase III, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2014-10-03","resultsPosted":"2015-08-07","lastUpdate":"2019-06-11"},"enrollment":1561,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"OTHER"},"conditions":["Prophylaxis: Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"TIVc_LOT A","otherNames":[]},{"type":"BIOLOGICAL","name":"TIVc_LOT B","otherNames":[]},{"type":"BIOLOGICAL","name":"TIVc_LOT C","otherNames":[]},{"type":"BIOLOGICAL","name":"TIVf","otherNames":[]}],"arms":[{"label":"TIVc-Lot A","type":"EXPERIMENTAL"},{"label":"TIVc-Lot B","type":"EXPERIMENTAL"},{"label":"TIVc-Lot C","type":"EXPERIMENTAL"},{"label":"TIVf","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the immunologic equivalence of three consecutive lots of a cell based trivalent subunit influenza vaccine (TIVc), and to assess immunogenicity, safety and tolerability of the vaccine and an egg based trivalent subunit influenza vaccine (TIVf).\n\nThe study comprised 1 vaccination, 2 clinic visits, 3 reminder calls and 2 blood draws. Female subjects of childbearing potential were tested for pregnancy before the administration of the vaccine and included only if using and agreeing to continue to use contraception during the course of the study.\n\nThe total study participation time per subject is about 3 weeks.","primaryOutcome":{"measure":"Immunologic Equivalence of 3 Consecutive Influenza Vaccine (TIVc) Production Lots.","timeFrame":"Day 22","effectByArm":[{"arm":"TIVc_LOT A","deltaMin":667,"sd":null},{"arm":"TIVc_LOT B","deltaMin":738,"sd":null},{"arm":"TIVc_LOT C","deltaMin":655,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":24,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":1169},"commonTop":["INJECTION SITE PAIN","HEADACHE","FATIGUE","INJECTION SITE ERYTHEMA","INJECTION SITE INDURATION"]}}